Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice (Q42244962)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 4 January 2014

Language	Label	Description	Also known as
English	Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice	scientific article published on 4 January 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Japanese encephalitis virus

0 references

Japanese encephalitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tick-borne encephalitis virus

object named as

tick-borne encephalitis virus

1 reference

based on heuristic

inferred from title

object named as

Cheng-Feng Qin

10

0 references

Yong-Qiang Deng

5

object named as

Yong-Qiang Deng

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

2

object named as

Xiao-Feng Li

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hong-Jiang Wang

1

object named as

Hong-Jiang Wang

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Qing Ye

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Shi-Hua Li

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Hui Zhao

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Yan-Peng Xu

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jie Ma

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

E-De Qin

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

4 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

949-956

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Specific clinical and epidemiological features of tick-borne encephalitis in Western Siberia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-Borne Encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis 2010: Epidemiology, risk areas, and virus strains in Europe and Asia—An overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis virus - a review of an emerging zoonosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis vaccines: past and present

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Field effectiveness of vaccination against tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tolerability of modified tick-borne encephalitis vaccine FSME-IMMUN "NEW" in children: results of post-marketing surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Two severe cases of tick-borne encephalitis despite complete active vaccination--the significance of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

The Golden Agers and Tick-borne encephalitis. Conference report and position paper of the International Scientific Working Group on Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Tick-borne encephalitis after vaccination: Vaccine failure or misdiagnosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Vaccine failures after active immunisation against tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area--impact on current recommendations for immunization of high-risk groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Rational design of a flavivirus vaccine by abolishing viral RNA 2'-O methylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Complete genome sequence analysis of tick-borne encephalitis viruses isolated in northeastern China

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1' formation and contributes to attenuation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Chimeric tick-borne encephalitis/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.050

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2013.12.050

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42244962&oldid=1939790779"